Charles River Laboratories (CRL) Tops Q2 EPS by 40c; lowers guidance

Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $2.80, $0.40 better than the analyst estimate of $2.40. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.02 billion.

GUIDANCE:

Charles River Laboratories sees FY2024 EPS of $9.90-$10.20, versus the consensus of $10.99.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.

You May Also Be Interested In

• Walmart to pay $1.4 billion for Vibe.co acquisition - WSJ
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Tenable Holdings, Inc. (TENB) call put ratio 80 calls to 1 put with a focus on 200 contracts of July 32 calls as share price up 5.6%